natgillin/translations-raw huggingface dataset:
binding said furin polypeptide or furin polypeptide derivative to a mixed cation exchange/hydrophobic interaction resin, 
(A) Vezivanje navedenog furin polipeptida ili skraćenog furin polipeptida na mješavinu smole za kationsku razmjenu / hidrofobnu interakciju,
However, it is to be understood than other designs of the capsule are viable, such as e.g. capsules having a lenticular form with two essentially matching and opposing walls (e.g. foils) being sealed at the e.g. ring-shaped edge. 
Međutim, treba razumjeti da su održive i druge izvedbe čahure, takve kao što su, na primjer, čahure koje imaju oblik leće s uglavnom dvije stijenke (na primjer folije) koje su usklađene jedna s drugom i nalaze se jedna nasuprot drugoj, pri čemu su brtvom spojene na, na primjer, rubu koji ima oblik prstena.
A non-naturally occurring and/or purified and/or engineered cell, especially a T-cell, presenting a TCR as claimed in any one of claims 1-12. 
Stanica koja ne postoji u prirodi i/ili je pročišćena i/ili konstruirana, koja prezentira TCR sukladno bilo kojem od patentnih zahtjeva 1-7.
A pharmaceutical combination comprising a therapeutically effective amount of a composition comprising: a first compound, the first compound being the compound of claim 1 or a pharmaceutically acceptable salt thereof; a second compound, the second compound being selected from the group consisting of a corticosteroid, hydroxychloroquine, cyclophosphamide, azathioprine, mycophenolate mofetil, methotrexate, janus kinase inhibitor, statin, calcipotriene, angiotensin-converting enzyme inhibitor and angiotensin receptor blocker; and 
Farmaceutska kombinacija, naznačena time što sadrži terapijski djelotvornu količinu pripravka koji sadrži: prvi spoj, gdje je prvi spoj spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol; drugi spoj, gdje se drugi spoj bira iz skupine koju čine kortikosteroid, hidroksiklorokin, ciklofosfamid, azatioprin, mikofenolat mofetil, metotreksat, inhibitor janus kinaze, statin, kalcipotrien, inhibitor angiotenzin-konvertirajućeg enzima i blokator angiotenzinskog receptora; i izborna farmaceutski prihvatljiva podloga, pomoćna tvar ili razrjeđivači.
ii) primary and/or metastatic GRPR+ cancer wherein the cancer is selected from prostate cancer, breast cancer, small cell lung cancer, colon carcinoma, gastrointestinal stromal tumors, gastrinoma, renal cell carcinomas, gastroenteropancreatic neuroendocrine tumors, oesophageal squamous cell tumors, neuroblastomas, head and neck squamous cell carcinomas, as well as in ovarian, endometrial and pancreatic tumors displaying neoplasia-related vasculature that is GRPR+; or 
Radiomarkirani GRPR-antagonist za uporabu prema zahtjevu 11, pri čemu je rak odabran od raka prostate, raka dojke, raka pluća malih stanica, karcinoma debelog crijeva, gastrointenstinalnih stromalnih tumora, gastrinoma, karcinoma renalnih stanica, neuroendokrinih tumora probavnog sustava i gušterače, tumora skvamoznih stanica jednjaka, neuroblastoma, karcinoma skvamoznih stanica glave i vrata, kao i tumora jajnika, endometrija i gušterače koji pokazuju vaskulaturu povezanu s neoplazijom koja je GRPR-pozitivna.
respectively and independently represents an unsubstituted or substituted C1-8 alkyl group, an unsubstituted or substituted C2-8 alkenyl group, an unsubstituted or substituted C2-8 alkynyl group, an unsubstituted or substituted hydroxyl group, a halogeno group, a cyano group or a nitro group. 
C2-8-alkinilnu skupinu, hidroksilnu skupinu, halogeno-skupinu, cijano-skupinu ili nitro-skupinu; m predstavlja broj skupina od X', koji je cijeli broj od 0 do 5; X" odnosno i neovisno predstavlja nesupstituiranu C1-8-alkilnu skupinu, nesupstituiranu C2-8-alkenilnu skupinu, nesupstituiranu
The present invention relates to a process for the preparation of trans 4-amino-cyclohexyl acetic acid ethyl ester HCl wherein the process comprises the following steps: step 1: 4-nitrophenyl acetic acid is hydrogenated in a protic solvent in the presence of Pd/C, at a temperature between 40-50 °C and under 0,1-0,6 bar overpressure; step 2: the 4-amino-nitrophenyl acetic acid obtained in situ in step 1 is further hydrogenated at a temperature between 50-60 °C and under 1-4 bar overpressures; step 3: the 4-amino-cxyclohexyl acetic acid obtained in step 2 is heated to reflux in hydrochloric ethanol for 1-3 hours and after removing the solvent by distilling in vacuum acetonitrile is added to the residue obtained and distilled off. 
HR P20140532 T1 PATENTNI ZAHTJEVI m Postupak pripreme trans-4-aminocikloheksiletil acetata HCI, naznačen time, da se dobije a) hidriranjem 4-nitrofenil octene kiseline u jednom protičkom otapalu, kod temperature između 40 do 50%C u prisutnosti Pd/C pod nadtlakom od 0,1 do 0,6 bara i b) daljnjim hidriranjem 4-aminofenil octene kiseline koja je in situ u koraku a) bila dobivena, kod temperature između 50 do 60*C pod nadtlakom od 1 do 4 bara, tada c) zagrijavanjem 4-aminocikloheksil octene kiseline, koja je dobivena u koraku b), uz povratno hlađenje preko 1 do 3 sata u klorovodik-etanolu i, ako je poželjno, bude nakon odstranjivanja otapala acetonitrila, dobivenom ostatku dodana i tada oddestilirana.
Example 1: Preparation of the liquid formulations 
Datum podnošenja europske prijave patenta:
Compounds of the formula I as claimed in one or more of claims 1 to 23 for use in the treatment and/or prevention of conditions which may be associated with the metabolic syndrome. 
Spojevi formule I u skladu s jednim ili više patentnih zahtjeva 1 do 23, namijenjeni upotrebi u liječenju i/ili sprječavanju stanja koja mogu biti povezana s metaboličkim sindromom.
Structure and synthesis of additional analogs or derivatives of nicotinic acid are discussed throughout the Merck Index, An Encyclopedia of Chemicals, Drugs, and Biologicals, Tenth Edition (1983), which is incorporated herein by reference in its entirety. 
Struktura i sinteze dodatnih analoga ili derivata nikotinske kiseline su prikazani kroz Merck Indeks, An Encyclopedia of Chemicals, Drugs, and Biologicals, tenth Edition (1983), što je ovdje sadržano u potpunosti zabilješkama.
the alkylcarbonyl, alkenylcarbonyl, and alkynylcarbonyl optionally are substituted with one or more substituents independently selected from the group consisting of carboxy, hydroxy, halo, amino, nitro, azido, oxo, aminosulfonyl, alkyloxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, alkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, alkyloxy, alkenyloxy, alkynyloxy, carbocyclyl, heterocyclyl, cyano, and aminocarbonyl, and the aminocarbonyl optionally is substituted with one or two substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkyloxyalkyl, carbocyclyl, heterocyclyl, alkylsulfonyl, and alkylsulfonylamino, wherein: 
alkilkarbonil, alkenilkarbonil i alkinilkarbonil su opcijski supstituirani s jednim ili više supstituenata neovisno odabranima iz skupine koju sačinjavaju karboksi, hidroksi, halo, amino, nitro, azido, okso, aminosulfonil, alkiloksikarbonil, alkeniloksikarbonil, alkiniloksikarbonil, alkilkarboniloksi, alkenilkarboniloksi, alkinilkarboniloksi, alkiloksi, alkeniloksi, alkiniloksi, karbociklil, heterociklil, cijano i aminokarbonil, i aminokarbonil je opcijski supstituiran s jednim ili dva supstituenta neovisno odabranima iz skupine koju sačinjavaju alkil, alkenil, alkinil, alkiloksialkil, karbociklil, heterociklil, alkilsulfonil i alkilsulfonilamino, pri čemu:
In some implementations, the membrane is made of a material such as flexible fabric, canvas, carbon fiber, sailcloth, para-aramid synthetic fiber, high-modulus polyethylene, ultra-high-molecular-weight polyethylene, thermoplastic polyethylene, rice paper, tissue paper, PTFE, liquid crystal polymers, and the like. 
Fleksibilno krilo (20) prema Zahtjevu 12, gdje je membrana (25) izrađena od materijala odabranog iz grupe koja sadrži fleksibilne tkanine, platna, ugljična vlakna, platna za jedra, sintetička vlakna od para-aramida, polietilene visoke molekularne težine, polietilene ultra-visoke molekularne težine, termoplastične polietilene, rižin papir, laki papir, PTFE, tkanine od tekućeg kristalnog polimera.
Once the refined phase is separated from the extract phase, if wished, it can be again contacted with one or more solvents in the conditions disclosed to form a second extract phase and a second refined phase, and the process of further extracting refined phases can be carried out if wished. In the acidulation step, the refined phase is contacted with a solution of an acid such as sulfuric acid, hydrochloric acid, phosphoric acid, acetic acid, trichloroacetic or carbonic acid, until an aqueous phase and a non aqueous phase comprising fatty acids are formed. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se u koraku (d) kiselina bira iz skupine koju čine sumporna kiselina, fosforna kiselina, octena kiselina, mravlja kiselina, trikloroctena kiselina i ugljična kiselina, temperatura je između 20 1 70%, tlak je otprilike 1 bar (100 kPa), a stehiometrijski omjer između kiseline 1 alkalije u koraku (a) je približno 1,05:1.
an obstacle element (20) placed on the foundation body (10), 
preprečni element (20), koji se nalazi na osnovnom tijelu (10), -
a plurality of sidewalls arising from a perimeter portion of the base of the bottom unit; each sidewall of said plurality defining therein a plurality of dunnage attachment points (41), each dunnage attachment point (41) comprising a slot that will allow an article of dunnage to be inserted and retained in said slot. 
više bočnih stjenki koje se dižu iz vanjskog ruba postolja donje jedinice; s tim da svaka bočna stjenka iz navedenog broja obuhvaća više pričvrsnih mjesta za zaštitni materijal (41), s tim da svako pričvrsno mjesto (41) ima utor u koji se komad zaštitnog materijala može umetnuti i u kojem ostaje.
More preferably, said pharmaceutical composition of the invention is for the treatment of progressive tumors, late stage tumors, tumor patients with high tumor load/burden, metastatic tumors, or tumor patients with a CEA serum concentration higher than 100 ng/ml. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 13, naznačen time što je navedeni farmaceutski pripravak namijenjen liječenju uznapredovalih tumora, kasnog stadija tumora, tumorskih pacijenata visoko opterećenih tumorom, metastazirajućih tumora ili tumorskih pacijenata s koncentracijom CEA u serumu višom od 100 ng/ml.
The amount of solid carrier will vary widely but will usually be from about 25 mg to about 1 g. 
Količina krutog nositelja jako će varirati, ali će obično biti od oko 25 mg do oko 1 g.
Use of a compound as defined in any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of a disorder mediated by inappropriate PI3-kinase activity. 
Upotreba kombinacije u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačena time što je kombinacija namijenjena proizvodnji medikamenta namijenjenog upotrebi u liječenju poremećaja uzrokovanog neodgovarajućom aktivnošću PI3-kinaze.
HL60 cells were seeded at 6×105 cells/mL in 20 mL RPMI-1640 medium supplemented with 10% fetal bovine serum, 1 mM glutamine and 20 uM gentamycin in a T75 flask and cultured overnight in 5% CO2 atmosphere at 37° C. The cells were treated with 0.1% DMSO or 20 uM of the test compounds (diethyl esters, compounds 1B to 12B and TLK199) in culture medium containing 0.1% DMSO for 2 hours. 
Stanice HL-60 zasijane kod 6x10* stanice/mL u 20 mL RPMI-1640 suplementnog medija sa 10% fetal bovin seruma, ImM glutamina i 20 uM gentamicina u T75 tikvici i kultura se razvijala preko noći u 5% CO2 atmosferi kod 37% €. Stanice su tretirane sa 0.1% DMSO ili 20 uM testnih spojeva (dietil esteri, spojevi 1B do 12B i TLK 199) u mediju kulture koji sadrži 0.1% DMSO 2 sata.
Mobile phase: SFC grade carbon dioxide and optima grade methanol with 1 mM disodium diethylmalonate modifier. 
Pokretna faza: ugljični dioksid SFC kvalitete i metanol optima kvalitete, uz 1 mM dinatrijev dietilmalonat kao modifikator.
Method of MR imaging wherein a subject previously administered with a composition according to claim 14 is subjected to an MR examination wherein MR signals are detected from the subject or parts of the subject into which the composition distributes and optionally MR images and/or MR spectra are generated from the detected signals. 
Postupak MR dijagnostike gdje se prethodno subjektu daje pripravak prema zahtjevu 14 te ga se podvrgava MR pregledu pri čemu se MR signali otkrivaju iz subjekta ili dijelova subjekta u koje se pripravak raspodjeljuje te se po izboru iz otkrivenih signala izrađuju MR slike i/ili MR spektar.
Y is CH or N, and p is an integer between 0 and 3, and salts thereof, either acid-addition salts with a pharmaceutically acceptable organic or mineral acid, or base-addition salts with a pharmaceutically acceptable organic or mineral base, and 
YjeCHiliN,i p je cijeli broj od 0 do 3, i njegove soli, bilo kiselinske adicijske soli s farmaceutski prihvatljivom organskom ili mineralnom kiselinom, ili lužnate adicijske soli s farmaceutski prihvatljivom organskom ili mineralnom lužinom, te najmanje jedno farmaceutski prihvatljivo pomoćno sredstvo.
The pharmaceutical composition to claim 1-4, wherein crospovidone is present in the core in a proportion of 1 - 5%. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 1-4, naznačen time što je umreženi povidon prisutan u jezgri u udijelu od 1-5%.
or a pharmaceutically acceptable salt or hydrate thereof; wherein the virus is selected from the group consisting of viruses of the orthomyxoviridae, paramyxoviridae, arenaviridae, bunyaviridae, flaviviridae, filoviridae, togaviridae, picornaviridae, and coronaviridae families. 
Spoj za uporabu sukladno zahtjevu 1, pri čemu virusna infekcija sadrži virus odabran iz skupine koja se sastoji od virusa iz obitelji orthomyxoviridae, paramyxoviridae, arenaviridae, bunyaviridae, flaviviridae, filoviridae, togaviridae, picornaviridae, i coronaviridae.
The method according to claim 1, wherein said beverage contains at the most 45 g/L sugar. The method according to claim 1, wherein the beverage contains in the range of 3 to 10 g/L organic acid. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time što napitak sadržava u rasponu od 3 do 10 g/L organske kiseline, kao što je u rasponu od 4 do 7 g/L organske kiseline.
ii) two or more nucleic acid molecules together comprising the adenovirus E1 A, the adenovirus E1B-19K coding sequence and the adenovirus E1B-55K coding sequence, wherein the E1A coding sequence and at least one of the E1B-19K and E1B-55K coding sequences are separated by at least 8 kb when the two or more nucleic acid molecules would form a single molecule by end-to-end joining before integrating into the precursor cell's genome; thus obtaining the packaging cell; 
Rekombinantna molekula koja sadrži sekvence nukleinske kiseline koje kodiraju adenovirusni ELA protein i barem jedan adenovirusni E1B protein, naznačena time da su navedena sekvenca nukleinske kiseline koja kodira ELA protein i sekvenca nukleinske kiseline koja kodira barem jedan E1B protein odvojene sa barem 8 kb, ili skupom od barem dvije molekule nukleinske kiseline koji bi tvorio navedenu rekombinantnu molekulu ako bi skup od barem dvije molekule nukleinske kiseline tvorio jednostruku molekulu spajanjem kraja sa krajem.
(c1) Oligo comprises poly (2,2 dimethyl-1-3-propylcarbonate) (PCN) polyol having a theoretical molecular weight of from 500 to 3,000 Daltons; 
[image] pri čemu Oligo sadrži polikarbonat poliol koji ima teorijsku molekulsku masu od 500 do 3000 Daltona
an immunoglobulin light chain of an IgG antibody, wherein the immunoglobulin heavy chain of (a) and the immunoglobulin light chain of (b) form an IgG antibody that binds B7RP1, wherein the protein comprises two molecules of the polypeptide of (a) and two molecules of the light chain of (b), wherein the protein can inhibit BAFF-mediated proliferation of human B cells, and wherein the protein can inhibit B7RP1-mediated proliferation of human T cells. 
laki lanac imunoglobulina IgG antitijela, naznačen time što teški lanac imunoglobulina iz (a) i laki lanac imunoglobulina iz (b) formiraju IgG antitijelo koje veže B7RP1, pri čemu protein sadrži dvije molekule polipeptida iz (a) i dvije molekule lakog lanca iz (b), pri čemu protein inhibira BAFF-posredovanu proliferaciju humanih B stanica, i pri čemu protein inhibira B7RP1-posredovanu proliferaciju humanih T stanica.
The method according to any one of the preceding embodiments, wherein the number of oil droplets having a size of >1.2 µm in the first emulsion is 5 x 1011 /ml or less. 
Postupak prema zahtjevu 1 ili zahtjevu 2, naznačen time da broj uljnih kapljica koje imaju veličinu od >1.2 um u prvoj emulziji je 5 x 10"! /ml ili manje.
The method of claim 4, wherein a binder is used which is soluble in the solvent. 
Postupak prema patentnom zahtjevu 4, gdje se upotrijebljava vezivo topivo u otapalu.
Compounds of Formula (I) hydrolyse, particularly under conditions where pH corresponds to that typically prevailing in the human stomach, to form a thiol and a uracil in a 1:1 stoichiometric ratio. 
Spojevi formule (1) hidroliziraju, naročito u uvjetima u kojima pH odgovara onome koji tipično prevladava u ljudskom želucu, da bi formirali tiol i uracil u 1:1 stehiometrijskom omjeru.
is selected from the group consisting of substituted or unsubstituted aryl, and 
Co 9 ž i R? je supstituiran ili nesupstituiran fenil.
The mixture was stirred for three hours at reflux temperature. 
Smjesa je miješana tijekom 3 sata na temperaturi refluksa.
An isoxazolic derivative of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of neuropathic pain. 
Izoksazolni derivat formule (I) u oH ili njegova farmaceutski prihvatljiva sol, naznačeni time, što se koriste za primjenu u liječenju neuropatskih bolova.
A composition according to claim 1 characterized in that erythritol is having a volume mean diameter of less than 100 µm, preferably less than 50 µm, more preferably less than 40 µm. 
Smjesa prema zahtjevu 1 naznačena time što eritritol ima srednji volumni promjer manji od 100 Pm, poželjno manji od 50 Pm, još poželjnije manji od 40 Pm.
The method of embodiments 29, further comprising, prior to (c), computationally removing allele frequencies for polymorphisms identified has being heterozygous in the pregnant individual. The method of embodiment 29, wherein the mixture model accounts for sequencing error. 
Postupak prema patentnim zahtjevima 1, naznačen time što nadalje sadrži, prije postupka (c), računalno uklanjanje učestalosti alela za polimorfizme koji su identificirani kao heterozigotni kod trudne osobe.
The compound of claim 1 wherein R1a, R1b and R1c are independently selected from the group consisting of: hydrogen, 
Spoj prema patentnom zahtjevu 1 gdje su R'*, R" i R'" nezavisno izabrani iz grupe koju čine:
A light source as claimed in claim 1, claim 2 or claim 3, wherein the plasma crucible is homogenous. A light source as claimed in any one of claims 1 to 4, wherein the plasma crucible is of circular cross-section and is dimensioned for a half wave to extend diametrically within it. 
Svjetlosni izvor u skladu s onim iz patentnog zahtjeva 1, patentnog zahtjeva 2 ili patentnog zahtjeva 3, naznačen time, da plazmena retorta ima kružni poprečni presjek i dimenzije koje omogućuju da se poluval širi dijametralnu unutarnje.
and then filtered, washed with ethyl acetate and dried in vacuo. 
i potom se filtrira, ispere sa etil acetatom i osuši u vakuumu.
The floating lake system of claim 1, wherein the system comprises a plurality of mobile suctioning devices, wherein the filtration system comprises a plurality of filters. 
Sustav plutajućeg jezera (1) prema zahtjevu 14, naznačen time što sustav obuhvaća veći broj pokretnih usisnih uređaja (42), pri čemu sustav za filtriranje (40) sadrži veći broj filtera.
subjecting the solution formed in step e) to a solid/liquid separation step, thereby to recover at least some of the metal sulphide and at least some of the hydrogen cyanide; and 
podvrgavanja otopine dobivene u koraku e) koraku odvajanja tekućine od krutina, čime se dobije u najmanju ruku dio metalnog sulfida i u najmanju ruku dio cijanovodika; i
It was filtered and the filtrate was washed with 1:1 heptane/IPAc and dried under vacuum at 40° C. to give a solid of Formula 37. 
Bila je filtrirana 1 filtrat je bio ispran s 1:1 heptanonVIPAc i osušen pod vakuumom kod 40"C da bi dao krutu tvar formule 37.
The method of claim 47, wherein the GPR119 agonist has an EC50 of less than 10 uM. 
Postupak u skladu sa zahtjevom 12 ili zahtjevom 13, naznačen time, da GPR119 agonist ima EC50 manji od 10 uM.
The gap sub (100) of claim 1, in which the first non-conductive coating is deployed on threads on both of the threaded pin end profile and the threaded box end profile. 
Razdvojni cijevni priključak (100) u skladu s patentnim zahtjevom 1, naznačen time što se prvu nevodljivu oblogu primjenjuje na navojima na oba od krajnjeg profila klina s navojem i krajnjeg profila kutije s navojem.
2001, 44, 1674-1689 by bromination of the corresponding toluene derivative, which is in turn obtained as described in J. Fluorine Chemistry, 2000. 101:85-89 . 
2001, 44, 1674-1689, bromiranjem odgovarajućeg derivata toluena, koje je dobiven kako je opisano u J. Fluorine Chemistry, 2000,101:85-89.
The formulation of clause 1, wherein the formulation has a therapeutic effect for a period of time selected from the group consisting of at least about four months to about one year, at least about four months to about six months and at least about three months to about five months. 
Formulacija prema zahtjevu 1, naznačena time, da formulacija ima terapeutski učinak za vremenski period koji je odabran iz skupine koju čine: najmanje oko četiri mjeseca do oko jedne godine, najmanje oko četiri mjeseca do oko šest mjeseci i najmanje oko tri mjeseca do oko pet mjeseci.
Compound Name Compound Code 2-(1-hydroxyethyl)-naphtho[2,3-b]furan-4,9-dione 
Kombinacija iz patentnog zahtjeva 1, pri čemu je prvi agens 2-acetilnafto[2,3-b]furan-4,9-dion ili njegova farmaceutski prihvatljiva sol ili solvat.
In another embodiment, the optimized viral polypeptide has the amino acid sequence of any one of the sequences set forth in SEQ NOS:1-29. 
Cjepivo prema zahtjevu 1, gdje spomenuto cjepivo sadrži spomenuti optimizirani virusni polipeptid koji ima sekvencu amino kiselina prikazanu u SEQ ID NO:9, te gdje spomenuto cjepivo nadalje sadrži:
Depending on the process conditions the end product of the Formula I is obtained either in neutral or salt form. 
Ovisno o uvjetima procesa, krajnji produkt s formulom I je dobiven ili u neutralnom obliku ili u obliku soli.